NAMPT as a Therapeutic Target against Stroke

Trends in Pharmacological Sciences

Volumn 36, Issue 12, 2015, Pages 891-905

  Wang, Pei ^a   Miao, Chao Yu ^a,b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b BEIJING INSTITUTE FOR BRAIN DISORDERS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; DAPORINAD; ENZYME INHIBITOR; GMX 1777; GMX 1778; NEUROPROTECTIVE AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE NUCLEOTIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE C EPSILON; RECOMBINANT ENZYME; RECOMBINANT NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; SIRTUIN 1; UNCLASSIFIED DRUG;

ANGIOGENESIS; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CRYSTAL STRUCTURE; DRUG SAFETY; DRUG TARGETING; ENDOTHELIAL PROGENITOR CELL; ENERGY CONSUMPTION; ENERGY METABOLISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME RELEASE; ENZYME SPECIFICITY; HUMAN; ISCHEMIC PRECONDITIONING; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE POTENTIAL DEPOLARIZATION; MOLECULAR DYNAMICS; NERVOUS SYSTEM FUNCTION; NEURAL STEM CELL; NEUROPROTECTION; NEURORESTORATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; ENZYMOLOGY; METABOLISM; MOLECULAR MODEL; MOLECULARLY TARGETED THERAPY; STROKE;

ANIMALS; HUMANS; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; STROKE;

EID: 84949521205     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2015.08.012     Document Type: Review

References (150)

1. M.J. O'Donnell, and et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study Lancet 376 2010 112 123
2. V.L. Feigin, and et al. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010 Lancet 383 2014 245 254
3. Z. Corbyn Statistics: a growing global burden Nature 510 2014 S2 S3
4. L. Liu, and et al. Stroke and stroke care in China: huge burden, significant workload, and a national priority Stroke 42 2011 3651 3654
5. U. Dirnagl, and M. Endres Found in translation preclinical stroke research predicts human pathophysiology, clinical phenotypes, and therapeutic outcomes Stroke 45 2014 1510 1518
6. P. Dibajnia, and C.M. Morshead Role of neural precursor cells in promoting repair following stroke Acta Pharmacol. Sin. 34 2013 78 90
7. U. Dirnagl Pathobiology of injury after stroke: the neurovascular unit and beyond Ann. N. Y. Acad. Sci. 1268 2012 21 25
8. P. Wang, and et al. Nicotinamide phosphoribosyltransferase protects against ischemic stroke through SIRT1-dependent adenosine monophosphate-activated kinase pathway Ann. Neurol. 69 2011 360 374
9. P. Wang, and et al. ARRB1/beta-arrestin-1 mediates neuroprotection through coordination of BECN1-dependent autophagy in cerebral ischemia Autophagy 10 2014 1535 1548
10. A.V. Kalueff, and et al. Rethinking CNS disorders: time for new drug targets? Trends Pharmacol. Sci. 35 2014 491 492
11. J. Preiss, and P. Handler Enzymatic synthesis of nicotinamide mononucleotide J. Biol. Chem. 225 1957 759 770
12. P.R. Martin, and et al. Identification of a plasmid-encoded gene from Haemophilus ducreyi which confers NAD independence J. Bacteriol. 183 2001 1168 1174
13. A. Rongvaux, and et al. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis Eur. J. Immunol. 32 2002 3225 3234
14. B. Samal, and et al. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor Mol. Cell. Biol. 14 1994 1431 1437
15. S. Ognjanovic, and et al. Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes J. Mol. Endocrinol. 26 2001 107 117
16. J.R. McGlothlin, and et al. Molecular cloning and characterization of canine pre-B-cell colony-enhancing factor Biochem. Genet. 43 2005 127 141
17. J.R. Revollo, and et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme Cell Metab. 6 2007 363 375
18. P. Wang, and et al. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide Cardiovasc. Res. 81 2009 370 380
19. M. Pittelli, and et al. Nicotinamide phosphoribosyltransferase (NAMPT) activity is essential for survival of resting lymphocytes Immunol. Cell Biol. 92 2014 191 199
20. +-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation Circ. Res. 97 2005 25 34
21. M. Tanaka, and et al. Visfatin is released from 3T3-L1 adipocytes via a non-classical pathway Biochem. Biophys. Res. Commun. 359 2007 194 201
22. A. Garten, and et al. Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes Biochem. Biophys. Res. Commun. 391 2010 376 381
23. D. Friebe, and et al. Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans Diabetologia 54 2011 1200 1211
24. E. Schilling, and S. Hauschildt Extracellular ATP induces P2X7-dependent nicotinamide phosphoribosyltransferase release in LPS-activated human monocytes Innate Immun. 18 2012 738 744
25. K. Kover, and et al. Expression and regulation of nampt in human islets PLoS ONE 8 2013 e58767
26. V.B. Pillai, and et al. Nampt secreted from cardiomyocytes promotes development of cardiac hypertrophy and adverse ventricular remodeling Am. J. Physiol. Heart Circ. Physiol. 304 2013 H415 H426
27. Y. Zhao, and et al. Extracellular visfatin has nicotinamide phosphoribosyltransferase enzymatic activity and is neuroprotective against ischemic injury CNS Neurosci. Ther. 20 2014 539 547
28. Z. Jing, and et al. Neuronal NAMPT is released after cerebral ischemia and protects against white matter injury J. Cereb. Blood Flow Metab. 34 2014 1613 1621
29. Y. Zhao, and et al. Regenerative neurogenesis after ischemic stroke promoted by nicotinamide phosphoribosyltransferase-nicotinamide adenine dinucleotide cascade Stroke 46 2015 1966 1974
30. C.Y. Miao Introduction: Adipokines and cardiovascular disease Clin. Exp. Pharmacol. Physiol. 38 2011 860 863
31. M. Fasshauer, and M. Bluher Adipokines in health and disease Trends Pharmacol. Sci. 36 2015 461 470
32. + biosynthetic machinery in mammalian cells FEBS J. 281 2014 5104 5119
33. + and function in mice Cell Metab. 21 2015 706 717
34. S. Kim, and et al. Central visfatin potentiates glucose-stimulated insulin secretion and beta-cell mass without increasing serum visfatin levels in diabetic rats Cytokine 65 2014 159 166
35. Y. Li, and et al. Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism J. Biol. Chem. 283 2008 34833 34843
36. V. Audrito, and et al. Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia Blood 125 2015 111 123
37. + biosynthetic enzyme Nat. Struct. Mol. Biol. 13 2006 661 662
38. J.A. Khan, and et al. Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents Nat. Struct. Mol. Biol. 13 2006 582 588
39. +-SIRT1 cascade improves post-ischaemic vascular repair by modulating Notch signalling in endothelial progenitors Cardiovasc. Res. 104 2014 477 488
40. E.S. Burgos, and et al. A phosphoenzyme mimic, overlapping catalytic sites and reaction coordinate motion for human NAMPT Proc. Natl. Acad. Sci. U.S.A. 106 2009 13748 13753
41. E.S. Burgos, and V.L. Schramm Weak coupling of ATP hydrolysis to the chemical equilibrium of human nicotinamide phosphoribosyltransferase Biochemistry 47 2008 11086 11096
42. C.Y. Miao, and Z.Y. Li The role of perivascular adipose tissue in vascular smooth muscle cell growth Br. J. Pharmacol. 165 2012 643 658
43. E.S. Burgos NAMPT in regulated NAD biosynthesis and its pivotal role in human metabolism Curr. Med. Chem. 18 2011 1947 1961
44. A. Rongvaux, and et al. Nicotinamide phosphoribosyl transferase/pre-B cell colony-enhancing factor/visfatin is required for lymphocyte development and cellular resistance to genotoxic stress J. Immunol. 181 2008 4685 4695
45. +: an old metabolite controlling new metabolic signaling pathways Endocr. Rev. 31 2010 194 223
46. + and sirtuins in aging and disease Trends Cell Biol. 24 2014 464 471
47. S. Ruggieri, and et al. Regulation of NAD biosynthetic enzymes modulates NAD-sensing processes to shape mammalian cell physiology under varying biological cues Biochim. Biophys. Acta 1854 2015 1138 1149
48. P. Wang, and et al. Loss of AMP-activated protein kinase-α2 impairs the insulin-sensitizing effect of calorie restriction in skeletal muscle Diabetes 61 2012 1051 1061
49. J. Song, and et al. Nicotinamide phosphoribosyltransferase is required for the calorie restriction-mediated improvements in oxidative stress, mitochondrial biogenesis, and metabolic adaptation J. Gerontol. A: Biol. Sci. Med. Sci. 69 2014 44 57
50. P. Wang, and et al. Circulating and local visfatin/Nampt/PBEF levels in spontaneously hypertensive rats, stroke-prone spontaneously hypertensive rats and Wistar-Kyoto rats J. Physiol. Sci. 60 2010 317 324
51. P. Wang, and et al. Visfatin is associated with lipid metabolic abnormalities in Lyon hypertensive rats Clin. Exp. Pharmacol. Physiol. 37 2010 894 899
52. + salvage pathway by CLOCK-SIRT1 Science 324 2009 654 657
53. + biosynthesis Science 324 2009 651 654
54. D. Polak-Jonkisz, and et al. Novel targets for pharmacological intervention in age-related diseases Trends Pharmacol. Sci. 35 2014 622 623
55. P. Bai, and et al. PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation Cell Metab. 13 2011 461 468
56. M.T. Barbosa, and et al. The enzyme CD38 (a NAD glycohydrolase EC 3.2.2.5) is necessary for the development of diet-induced obesity FASEB J. 21 2007 3629 3639
57. + metabolism, protein acetylation, and treatment of metabolic syndrome Diabetes 62 2013 1084 1093
58. + depletion and reduced Sir2α deacetylase activity J. Biol. Chem. 280 2005 43121 43130
59. S. Wang, and et al. Cellular NAD depletion and decline of SIRT1 activity play critical roles in PARP-1-mediated acute epileptic neuronal death in vitro Brain Res. 1535 2013 14 23
60. + depletion is necessary and sufficient for poly(ADP-ribose) polymerase-1-mediated neuronal death J. Neurosci. 30 2010 2967 2978
61. S.J. Won, and et al. Prevention of traumatic brain injury-induced neuron death by intranasal delivery of nicotinamide adenine dinucleotide J. Neurotrauma 29 2012 1401 1409
62. + administration significantly attenuates synchrotron radiation X-ray-induced DNA damage and structural alterations of rodent testes Int. J. Physiol. Pathophysiol. Pharmacol. 4 2012 1 9
63. W. Zhang, and et al. Neuronal protective role of PBEF in a mouse model of cerebral ischemia J. Cereb. Blood Flow Metab. 30 2010 1962 1971
64. L.R. Stein, and S. Imai Specific ablation of Nampt in adult neural stem cells recapitulates their functional defects during aging EMBO J. 33 2014 1321 1340
65. M. Hallschmid, and et al. Relationship between cerebrospinal fluid visfatin (PBEF/Nampt) levels and adiposity in humans Diabetes 58 2009 637 640
66. M. Endres, and et al. Ischemic brain injury is mediated by the activation of poly(ADP-ribose)polymerase J. Cereb. Blood Flow Metab. 17 1997 1143 1151
67. J. Yang, and et al. The effects of nicotinamide on energy metabolism following transient focal cerebral ischemia in Wistar rats Neurosci. Lett. 333 2002 91 94
68. K.C. Morris-Blanco, and et al. Protein kinase C epsilon regulates mitochondrial pools of Nampt and NAD following resveratrol and ischemic preconditioning in the rat cortex J. Cereb. Blood Flow Metab. 34 2014 1024 1032
69. L.F. Lu, and et al. Elevated visfatin/pre-B-cell colony-enhancing factor plasma concentration in ischemic stroke J. Stroke Cerebrovasc. Dis. 18 2009 354 359
70. N.P. Kadoglou, and et al. Serum levels of novel adipokines in patients with acute ischemic stroke: potential contribution to diagnosis and prognosis Peptides 57 2014 12 16
71. Q. Kong, and et al. Increased serum visfatin as a risk factor for atherosclerosis in patients with ischaemic cerebrovascular disease Singapore Med. J. 55 2014 383 387
72. C.G. Yin, and et al. Prognostic significance of plasma visfatin levels in patients with ischemic stroke Peptides 42 2013 101 104
73. Q. Huang, and et al. High concentrations of visfatin in the peripheral blood of patients with acute basal ganglia hemorrhage are associated with poor outcome Peptides 39 2013 55 58
74. S.J. Gu, and et al. Admission plasma visfatin level strongly correlates with hematoma growth and early neurologic deterioration in patients with acute spontaneous basal ganglia hemorrhage Clin. Chim. Acta 425 2013 85 89
75. J. Chen, and et al. Change in plasma visfatin level after severe traumatic brain injury Peptides 38 2012 8 12
76. J.F. Weng, and et al. Plasma visfatin, associated with a genetic polymorphism -1535C>T, is correlated with C-reactive protein in Chinese Han patients with traumatic brain injury Peptides 40 2013 8 12
77. A. Korner, and et al. Molecular characteristics of serum visfatin and differential detection by immunoassays J. Clin. Endocrinol. Metab. 92 2007 4783 4791
78. K. Shah, and T. Abbruscato The role of blood-brain barrier transporters in pathophysiology and pharmacotherapy of stroke Curr. Pharm. Des. 20 2014 1510 1522
79. W.Y. Liu, and D.F. Su Blood-brain barrier is not a barrier in the development of new drugs for ischemic stroke CNS Neurosci. Ther. 20 2014 1013 1014
80. S.K. Bae, and et al. Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1 FEBS Lett. 580 2006 4105 4113
81. S. Yang, and et al. NAMPT (visfatin), a direct target of hypoxia-inducible factor-2α, is an essential catabolic regulator of osteoarthritis Ann. Rheum. Dis. 74 2015 595 602
82. Y.S. Kang, and et al. Visfatin induces neurite outgrowth in PC12 cells via ERK1/2 signaling pathway Neurosci. Lett. 504 2011 121 126
83. R.A. Billington, and et al. NAD depletion by FK866 induces autophagy Autophagy 4 2008 385 387
84. J. Bi, and et al. Pre-B-cell colony-enhancing factor exerts a neuronal protection through its enzymatic activity and the reduction of mitochondrial dysfunction in in vitro ischemic models J. Neurochem. 120 2012 334 346
85. S. Wang, and et al. Cellular NAD replenishment confers marked neuroprotection against ischemic cell death: role of enhanced DNA repair Stroke 39 2008 2587 2595
86. P. Wang, and et al. Induction of autophagy contributes to the neuroprotection of nicotinamide phosphoribosyltransferase in cerebral ischemia Autophagy 8 2012 77 87
87. S. Erfani, and et al. Nampt/PBEF/visfatin exerts neuroprotective effects against ischemia/reperfusion injury via modulation of Bax/Bcl-2 ratio and prevention of caspase-3 activation J. Mol. Neurosci. 56 2015 237 243
88. S. Erfani, and et al. Visfatin reduces hippocampal CA1 cell death and improves learning and memory deficits after transient global ischemia/reperfusion Neuropeptides 49 2015 63 68
89. S. Erfani, and et al. Visfatin inhibits apoptosis and necrosis of hippocampus CA3 cells following transient global ischemia/reperfusion in rats Int. J. Pept. Res. Ther. 21 2015 223 228
90. + administration decreases ischemic brain damage partially by blocking autophagy in a mouse model of brain ischemia Neurosci. Lett. 512 2012 67 71
91. W. Zhang, and et al. Pressor and non-pressor effects of sodium loading on stroke in stroke-prone spontaneously hypertensive rats Clin. Exp. Pharmacol. Physiol. 35 2008 83 88
92. J.M. Guo, and et al. Nicotinamide postpones stroke in stroke-prone spontaneously hypertensive rats CNS Neurosci. Ther. 18 2012 267 268
93. P. Wang, and et al. Visfatin and cardio-cerebro-vascular disease J. Cardiovasc. Pharmacol. 59 2012 1 9
94. J.R. Marler, and et al. Morning increase in onset of ischemic stroke Stroke 20 1989 473 476
95. + levels dictate cell survival Cell 130 2007 1095 1107
96. B.P. Hubbard, and D.A. Sinclair Small molecule SIRT1 activators for the treatment of aging and age-related diseases Trends Pharmacol. Sci. 35 2014 146 154
97. Y. Hattori, and et al. Silent information regulator 2 homolog 1 counters cerebral hypoperfusion injury by deacetylating endothelial nitric oxide synthase Stroke 45 2014 3403 3411
98. M. Hernandez-Jimenez, and et al. Silent information regulator 1 protects the brain against cerebral ischemic damage Stroke 44 2013 2333 2337
99. K.C. Morris, and et al. Pathways for ischemic cytoprotection: role of sirtuins in caloric restriction, resveratrol, and ischemic preconditioning J. Cereb. Blood Flow Metab. 31 2011 1003 1019
100. Y. Yang, and et al. Melatonin prevents cell death and mitochondrial dysfunction via a SIRT1-dependent mechanism during ischemic-stroke in mice J. Pineal Res. 58 2015 61 70
101. J. Yin, and et al. Sirtuin 3 mediates neuroprotection of ketones against ischemic stroke J. Cereb. Blood Flow Metab. 2015 10.1038/jcbfm.2015.123 Published online June 10, 2015
102. Q. Wang, and et al. SIRT3 protects cells from hypoxia via PGC-1α- and MnSOD-dependent pathways Neuroscience 286 2015 109 121
103. Y. Hu, and et al. Sirtuin 6 is essential for sodium sulfide-mediated cytoprotective effect in ischemia/reperfusion-stimulated brain endothelial cells J. Stroke Cerebrovasc. Dis. 24 2015 601 609
104. M.J. Eliasson, and et al. Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia Nat. Med. 3 1997 1089 1095
105. S.A. Andrabi, and et al. Iduna protects the brain from glutamate excitotoxicity and stroke by interfering with poly(ADP-ribose) polymer-induced cell death Nat. Med. 17 2011 692 699
106. -/- mouse Biochem. Biophys. Res. Commun. 346 2006 188 192
107. C.U. Choe, and et al. CD38 exacerbates focal cytokine production, postischemic inflammation and brain injury after focal cerebral ischemia PLoS ONE 6 2011 e19046
108. Z.G. Zhang, and M. Chopp Neurorestorative therapies for stroke: underlying mechanisms and translation to the clinic Lancet Neurol. 8 2009 491 500
109. S.R. Kim, and et al. Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2 Biochem. Biophys. Res. Commun. 357 2007 150 156
110. R. Adya, and et al. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis Cardiovasc. Res. 78 2008 356 365
111. F. Lovren, and et al. Visfatin activates eNOS via Akt and MAP kinases and improves endothelial cell function and angiogenesis in vitro and in vivo: translational implications for atherosclerosis Am. J. Physiol. Endocrinol. Metab. 296 2009 E1440 E1449
112. P. Wang, and et al. Nicotinamide phosphoribosyltransferase facilitates post-stroke angiogenesis CNS Neurosci. Ther. 21 2015 475 477
113. J. Chang, and et al. Nicotinamide adenine dinucleotide (NAD)-regulated DNA methylation alters CCCTC-binding factor (CTCF)/cohesin binding and transcription at the BDNF locus Proc. Natl. Acad. Sci. U.S.A. 107 2010 21836 21841
114. T. Hathorn, and et al. Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington's disease Neurobiol. Dis. 41 2011 43 50
115. T. Araki, and et al. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration Science 305 2004 1010 1013
116. + destruction Science 348 2015 453 457
117. L.R. Stein, and et al. Expression of Nampt in hippocampal and cortical excitatory neurons is critical for cognitive function J. Neurosci. 34 2014 5800 5815
118. R.Y. Zhang, and et al. A fluorometric assay for high-throughput screening targeting nicotinamide phosphoribosyltransferase Anal. Biochem. 412 2011 18 25
119. T.Y. Xu, and et al. Discovery and characterization of novel small-molecule inhibitors targeting nicotinamide phosphoribosyltransferase Sci. Rep. 5 2015 10043
120. X. Wang, and et al. Discovery of novel inhibitors and fluorescent probe targeting NAMPT Sci. Rep. 5 2015 12657
121. D. Sampath, and et al. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer Pharmacol. Ther. 151 2015 16 31
122. G. Wang, and et al. P7C3 neuroprotective chemicals function by activating the rate-limiting enzyme in NAD salvage Cell 158 2014 1324 1334
123. A.A. Pieper, and et al. Discovery of a proneurogenic, neuroprotective chemical Cell 142 2010 39 51
124. K.S. MacMillan, and et al. Development of proneurogenic, neuroprotective small molecules J. Am. Chem. Soc. 133 2011 1428 1437
125. H. De Jesus-Cortes, and et al. Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of Parkinson disease Proc. Natl. Acad. Sci. U.S.A. 109 2012 17010 17015
126. R. Tesla, and et al. Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of amyotrophic lateral sclerosis Proc. Natl. Acad. Sci. U.S.A. 109 2012 17016 17021
127. T.C. Yin, and et al. P7C3 neuroprotective chemicals block axonal degeneration and preserve function after traumatic brain injury Cell Rep. 8 2014 1731 1740
128. L.M. Dutca, and et al. Early detection of subclinical visual damage after blast-mediated TBI enables prevention of chronic visual deficit by treatment with P7C3-S243 Invest. Ophthalmol. Vis. Sci. 55 2014 8330 8341
129. A.K. Walker, and et al. The P7C3 class of neuroprotective compounds exerts antidepressant efficacy in mice by increasing hippocampal neurogenesis Mol. Psychiatry 20 2015 500 508
130. S.E. Latchney, and et al. Chronic P7C3 treatment restores hippocampal neurogenesis Neurosci. Lett. 591 2015 86 92
131. S.W. Kemp, and et al. Pharmacologic rescue of motor and sensory function by the neuroprotective compound P7C3 following neonatal nerve injury Neuroscience 284 2015 202 216
132. U. Dirnagl, and et al. Preconditioning and tolerance against cerebral ischaemia: from experimental strategies to clinical use Lancet Neurol. 8 2009 398 412
133. Y. Wang, and et al. Ischemic conditioning-induced endogenous brain protection: applications pre-, per- or post-stroke Exp. Neurol. 350 2015
134. R. Sheng, and Z.H. Qin The divergent roles of autophagy in ischemia and preconditioning Acta Pharmacol. Sin. 36 2015 411 420
135. M.A. Cline, and et al. Central visfatin causes orexigenic effects in chicks Behav. Brain Res. 186 2008 293 297
136. S.Y. Lim, and et al. The novel adipocytokine visfatin exerts direct cardioprotective effects J. Cell. Mol. Med. 12 2008 1395 1403
137. B. Zhao, and et al. Cerebral ischemia is exacerbated by extracellular nicotinamide phosphoribosyltransferase via a non-enzymatic mechanism PLoS ONE 8 2013 e85403
138. F. Van Gool, and et al. Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuin-dependent manner Nat. Med. 15 2009 206 210
139. E. Esposito, and et al. The NAMPT inhibitor FK866 reverts the damage in spinal cord injury J. Neuroinflamm. 9 2012 66
140. + depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE PLoS ONE 4 2009 e7897
141. + T-cell differentiation Nat. Commun. 5 2014 5101
142. R.B. Caldwell, and et al. Arginase: an old enzyme with new tricks Trends Pharmacol. Sci. 36 2015 395 405
143. D.J. Cook, and et al. Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain Nature 483 2012 213 217
144. S. Shinozaki, and et al. Inflammatory stimuli induce inhibitory S-nitrosylation of the deacetylase SIRT1 to increase acetylation and activation of p53 and p65 Sci. Signal. 7 2014 ra106
145. I. Mattagajasingh, and et al. SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase Proc. Natl. Acad. Sci. U.S.A. 104 2007 14855 14860
146. Z.Y. Li, and et al. Subfatin is a novel adipokine and unlike Meteorin in adipose and brain expression CNS Neurosci. Ther. 20 2014 344 354
147. A. Moscardo, and et al. The histone deacetylase sirtuin 2 is a new player in the regulation of platelet function J. Thromb. Haemost. 13 2015 1335 1344
148. S.S. Barbieri, and et al. Cyclooxygenase-2-derived prostacyclin regulates arterial thrombus formation by suppressing tissue factor in a sirtuin-1-dependent-manner Circulation 126 2012 1373 1384
149. M.A. Lancaster, and J.A. Knoblich Organogenesis in a dish: modeling development and disease using organoid technologies Science 345 2014 1247125
150. D.J. Cook, and M. Tymianski Nonhuman primate models of stroke for translational neuroprotection research Neurotherapeutics 9 2012 371 379